Characterization of rituximab-induced B cell depletion and infusion reactions in a human blood loop system
Introduction: Rituximab is a monoclonal antibody used to treat hematological malignancies. The antibody depletes CD20+ B cells via cytotoxic immune mechanisms, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), which is mainly induced by natural...
| Main Author: | |
|---|---|
| Format: | Others |
| Language: | English |
| Published: |
Uppsala universitet, Institutionen för farmaceutisk biovetenskap
2020
|
| Subjects: | |
| Online Access: | http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-414582 |